UNSPSC 51343826: Sofosbuvir/Velpatasvir

Sofosbuvir/velpatasvir is a fixed-dose combination medication for the treatment of hepatitis C in adults.

UNSPSC 51343826 Sofosbuvir/Velpatasvir is a Commodity code naming a hepatitis C antiviral combination therapy, yet the recent state and local opportunities posted under this code do not align with the pharmaceutical product itself. Of the twelve opportunities tagged with this code in the source, none solicit Sofosbuvir/Velpatasvir or any hepatitis C treatment; instead, they span EMS drug-dosage calculation software (Collier County), long-term care pharmacy services (Dane County), naloxone distribution systems (Washington County and Seminole County), BLS/ALS pharmaceuticals and vending machines (Tucson), general psychiatric pharmacy services (West Texas Centers), forensic drug standards (Pinellas County), and networking events or administrative notices bearing no procurement substance. The mislabeling suggests either a cataloging error in the state procurement databases or use of the code as a catch-all placeholder for pharmaceutical-adjacent activities that do not correspond to a direct-drug-procurement taxonomy. State and local governments appear to use this code inconsistently across multiple states—Florida (Collier, Seminole, Pinellas, Marion), Wisconsin (Dane), Oregon (Washington), Kentucky (Owensboro), California (San Mateo), Arizona (Tucson), Texas (West Texas Centers, Williamson), and DC (District of Columbia)—but the activities solicited bear no coherent relationship to each other or to the code's nominal scope.

No recent state or local opportunities actually seek Sofosbuvir/Velpatasvir or similar direct hepatitis C pharmaceutical procurement. The code shows little relevant recent activity aligned with its stated product line; business development professionals should verify the correct commodity or family code for hepatitis C therapeutics or pharmacy benefit management before pursuing opportunities tagged here.